| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Liraglutide |
| Brand | Victoza® |
| Indication | For treatment of adults with type 2 diabetes mellitus. |
| Assessment Process | |
| Rapid review commissioned | 01/09/2009 |
| Rapid review completed | 07/10/2009 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Not Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 26/10/2016 |
| Pre-submission consultation with Applicant | 21/02/2017 |
| Full submission received from Applicant | 29/08/2017 |
| Preliminary review sent to Applicant | 17/08/2018 |
| NCPE assessment re-commenced | 30/10/2018 |
| Factual accuracy sent to Applicant | 07/02/2019 |
| NCPE assessment re-commenced | 18/02/2019 |
| NCPE assessment completed | 07/03/2019 |
| NCPE assessment outcome | The NCPE recommends that liraglutide (Victoza®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013
